Breaking Barriers: Safely Targeting Obstructive Hypertrophic Cardiomyopathy at the Source : Episode 5
Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice
Anjali Tiku Owens, MD, shares insights into how their institution or clinic implements the Risk Evaluation and Mitigation Strategy (REMS) program for mavacamten, detailing the requirements and responsibilities of the patient in the process. Additionally, the expert draws upon their real-world experience with the cardio myosin inhibitor (CMI) in clinical practice, providing valuable perspectives on the practical application of this novel drug class.
EP: 1.Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause
EP: 2.Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment
EP: 3.Aligning With 2023 ESC Guidelines in oHCM Treatment
EP: 4.Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes
Now Viewing
EP: 5.Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice
Recent Videos
Related Content
